Clinical Trials Sponsored by Urigen

Total 439 results

Urigen

Completed

Study of U101 for Bladder Pain and/or Urgency

Pelvic Pain | Interstitial Cystitis | Bladder Diseases

United States
Urigen

Terminated

Engage 24: Evaluation of the Safety and Effectiveness of URG101 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome

Interstitial Cystitis | Bladder Pain Syndrome

United States
Urigen

Completed

Study of URG101 in Painful Bladder Syndrome and Interstitial Cystitis

Interstitial Cystitis | Painful Bladder Syndrome

United States
UroGen Pharma Ltd.

Not yet recruiting

A Phase 3 Study of UGN-103 for Treatment of Patients With Low-grade Intermediate-risk Non-muscle Invasive Bladder Cancer (UTOPIA)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma
UroGen Pharma Ltd.

Recruiting

A Phase 1 Dose-escalation Study of UGN-301 in Patients With Recurrent Non-muscle Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Non-muscle Invasive Bladder Cancer | Urothelial Carcinoma Bladder | NMIBC | Urothelial Carcinoma Recurrent | Carcinoma in Situ of Bladder

United States, Italy, Spain
UroGen Pharma Ltd.

Completed

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study (Olympus)

Carcinoma, Transitional Cell | Transitional Cell Carcinoma of Renal Pelvis

United States, Israel
UroGen Pharma Ltd.

Completed

Efficacy and Safety of Intravesical Instillations of Botulinum Toxin in TC-3 Gel in IC Patients

Interstitial Cystitis | IC

Israel
UroGen Pharma Ltd.

Completed

Safety and Tolerability Study Which Evaluate Intravesical Instillation With Mitomycin C Mixed With TC-3 Drug Retaining Hydrogel Device In Patients With Muscle Invasive Bladder Cancer

Carcinoma of Urinary Bladder, Invasive

Israel
aRigen Pharmaceuticals, Inc.

Unknown

Study to Compare Efficacy of Topical ARYS-01 (Sorivudine) Cream 3%, Oral Valaciclovir and Combination ARYS-01 Cream 3%/Oral Valaciclovir for Treatment of Herpes Zoster (Shingles)

Herpes Zoster | Postherpetic Neuralgia

United States
AuriGen Medical Ltd

Recruiting

Zenith LAA Occlusion System

Stroke | Atrial Fibrillation | Left Atrial Appendage

New Zealand
UroGen Pharma Ltd.

Recruiting

uTRACT Jelmyto Registry: A Registry of Patients With Upper Tract Urothelial Cancer (UTUC) Treated With Jelmyto (uTRACT)

Carcinoma, Transitional Cell | Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent | Transitional Cell Carcinoma of Renal Pelvis

United States
UroGen Pharma Ltd.

Active, not recruiting

A Phase 3 Single-Arm Study of UGN-102 for Treatment of Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (ENVISION)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Spain, Lithuania, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Austria
UroGen Pharma Ltd.

Terminated

A Phase 3 Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle Invasive Bladder Cancer (ATLAS)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel, Russian Federation, Georgia, Bulgaria, Estonia, Latvia, Poland, Serbia, Ukraine
UroGen Pharma Ltd.

Withdrawn

Efficacy and Safety of UGN-101 in Recurrent Patients (Retreatment)

Carcinoma | Transitional Cell Carcinoma | Transitional Cell Cancer of the Renal Pelvis and Ureter

Israel, United States
UroGen Pharma Ltd.

Withdrawn

Safety and Efficacy Study of Intravesical Instillations of BotuGelTM, Slow Release RTGel Based Botox® Formulations, in Idiopathic OAB Patients With Urinary Incontinence ("INTIMO2") (INTIMO2)

Overactive Bladder

Israel
UroGen Pharma Ltd.

Completed

Pilot Study to Evaluate the Clinical Response to Mitomycin-C in Hydrogel (TC-3) Administered Intravesically in NMIBC Patients

Neoplasms | Urologic Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Urinary Bladder Neoplasms

India
UroGen Pharma Ltd.

Withdrawn

A Prospective Open Label Comparative Dose Ranging Study Evaluating the Effect of Pre-TURBT Intravesical Instillation of Mitomycin C (MMC) Mixed With TC-3 Gel in Patients With Non Muscle Invasive Bladder Cancer (NMIBC) (NMIBC TURBT HG)

Non Muscle Invasive Bladder Cancer

Israel
UroGen Pharma Ltd.

Completed

Feasibility of Home Instillation of UGN-102 for Treatment of Low-Grade (LG) Non-Muscle-Invasive Bladder Cancer (NMIBC)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States
UroGen Pharma Ltd.

Completed

A Phase 2b Study of UGN-102 for Low Grade Intermediate Risk Non-Muscle-Invasive Bladder Cancer (OPTIMA II)

Bladder Cancer | Urothelial Carcinoma Bladder | Urothelial Carcinoma

United States, Israel
UroGen Pharma Ltd.

Completed

Pre-TURBT TC-3 Gel Intravesical Instillation in NMIBC (OPTIMA)

Carcinoma of Urinary Bladder, Superficial

Israel, Spain, Italy, Switzerland
UroGen Pharma Ltd.

Completed

Safety of Pre-TURBT Intravesical Instillation of Escalating Doses of TC-3 Gel and MMC in NMIBC Patients

Neoplasms | Urologic Diseases | Urinary Bladder Diseases | Bladder Cancer

Israel
UroGen Pharma Ltd.

Terminated

Safety and Efficacy of Intravesical Botulinum Toxin in TC-3 Gel in OAB Patients

Overactive Bladder

Israel
Avigen

Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Associated With Multiple Sclerosis

Muscle Spasticity

Czech Republic, Ukraine, Germany, Russian Federation, Serbia
Avigen

Terminated

Safety and Preliminary Effectiveness of AV650 in Patients With Spasticity Due to Spinal Cord Injury

Muscle Spasticity

United States, Canada
Avigen

Completed

AV650 Drug-Drug Interaction Study

Healthy

United States
Avigen

Completed

Study to Examine the Safety, Tolerability, and Pharmacokinetics of AV650

Healthy Subjects

United States
Avigen

Completed

Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of AV411 in Neuropathic Pain

Diabetic Neuropathy

Australia
Qurgen Inc.

Recruiting

A First-in-Human Study of SON-DP in Participants With Relapsed/Refractory Intolerant to Standard of Care Therapies for Advanced/Metastatic Solid Tumors

Breast Cancer | Colorectal Cancer | Pancreatic Cancer | Ovarian Cancer | Solid Tumor

United States
Origin Biosciences

Completed

Study of ORGN001 (Formerly ALXN1101) in Neonates, Infants and Children With Molybdenum Cofactor Deficiency (MOCD) Type A

Molybdenum Cofactor Deficiency, Type A

United States, Spain, Israel, Norway, Turkey, United Kingdom
Origin Inc.

Unknown

A Feasibility Study of Advance Plasma Therapy001 Plasma/Nitric Oxide Therapy for the Treatment of Diabetic Foot Ulcers

Diabetic Foot Ulcer

United States
Progen Pharmaceuticals

Completed

Study of CGC-11047 When Used in Individual Combinations With 1) Gemcitabine or 2) Docetaxel or 3) Bevacizumab or 4) Erlotinib or 5) Cisplatin or 6) 5-Flurouracil or 7) Sunitinib in Patients With Advanced Solid Tumors or Lymphoma

Cancer

United States
Origin Inc.

Completed

APT001 Plasma/NO Generator to Treat Diabetic Foot Ulcer in Adults (APT-14-002)

Foot Ulcer, Diabetic

United States
Progen Pharmaceuticals

Completed

Safety of 16.5 mg (3.3%) CGC-11047 Once Every 2 Weeks vs. Once Every 4 Weeks in Patients With CNV Due to AMD

Age Related Macular Degeneration

United States, Mexico, Russian Federation
Origin Biosciences

Completed

Safety & Efficacy Study of ORGN001 (Formerly ALXN1101) in Pediatric Patients With MoCD Type A Currently Treated With rcPMP

Molybdenum Cofactor Deficiency, Type A

United States, Australia, Netherlands, United Kingdom, Tunisia
Origin Sciences

Completed

Exploratory Study of Rectal Mucus for Diagnosing Disease (ORI-EGI-02)

Bowel Cancer | Bowel Disease | Epigenetic Disorder | Genomic

United Kingdom
Origin Biosciences

Completed

A Retrospective, Observational, Noninterventional Data Collection Study for Patients With Molybdenum Cofactor Deficiency Who Have Been Previously Treated With Cyclic Pyranopterin Monophosphate (cPMP)

Molybdenum Cofactor Deficiency

United States, Australia, United Kingdom, Germany, Netherlands, Turkey
Progen Pharmaceuticals

Completed

Study of CGC-11047 (PG-11047) in Subjects With Advanced Refractory Solid Tumors

Cancer

United States
Progen Pharmaceuticals

Terminated

Phase III Study of PI-88 in Post-resection Hepatocellular Carcinoma (PATHWAY)

Cancer | Hepatocellular Carcinoma | Primary Liver Cancer | Liver Cancer | Hepatoma

Hong Kong, Singapore, United States, Australia, Canada, Italy, Malaysia, Spain, Taiwan, Thailand
Origin Biosciences

Completed

A Natural History Study of Molybdenum Cofactor and Isolated Sulfite Oxidase Deficiencies

Molybdenum Cofactor Deficiency | Isolated Sulfite Oxidase Deficiency

Spain, Israel, United States, United Kingdom, Canada, Netherlands, Germany, Saudi Arabia, Tunisia, Japan, Italy, Malaysia, Poland, Turkey
Origin Biosciences

Completed

Phase 1 Single Dose Study of ALXN1101 in Healthy Volunteers

Molybdenum Cofactor Deficiency (MoCD) | Rare Autosomal Recessive Disorder | Deficiency of Activity of Molybdenum-dependent Enzymes (Sulfite Oxidase [SOX], Xanthine Dehydrogenase, and Aldehyde Oxidase)

United States
UroGen Pharma Ltd.
Tanner Pharma Group

Available

Named Patient Program for Mitomycin for Pyelocalyceal Solution

Urothelial Carcinoma | Urothelial Cancer of Renal Pelvis | Urothelial Carcinoma Ureter | Urothelial Carcinoma Recurrent | Urothelial Carcinoma of the Renal Pelvis and Ureter | Urothelial Carcinoma Ureter Recurrent
ProGen. Co., Ltd.

Recruiting

A Study to Assess Safety, Pharmacokinetics and Pharmacodynamics of PG-102(MG12) in Healthy Volunteers

Healthy | Overweight

Korea, Republic of
Auregen Biotherapeutics, SA

Recruiting

Long-Term Follow-Up Study of Unilateral Microtia Patients Implanted With AUR-201 (AUR-201)

Microtia

United States
Auregen Biotherapeutics, SA

Recruiting

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (AUR-201)

Microtia

United States
AuraGen Aesthetics LLC

Terminated

Prospective Comparison of Revolve™ and AuraGen 123 With AuraClens™ in Autologous Fat Grafting to the Breast

Autologous Fat Grafting

United States
Auregen Biotherapeutics, SA

Enrolling by invitation

Subcutaneous Implant Combination Product (AUR-201) in Patients With Unilateral Microtia (Australia) (AUR-201)

Microtia

Australia
Rigel Pharmaceuticals

Terminated

Observational Study of Fostamatinib as Second Line Therapy in Adult Patients With Immune Thrombocytopenia (ITP) and Insufficient Response to a Prior Therapy

Immune Thrombocytopenia | ITP

United States
Rigel Pharmaceuticals

Completed

Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy

IGA Nephropathy

United States, United Kingdom, Hong Kong, Taiwan, Austria, Germany
Xigen SA

Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

Pain | Inflammation | Cataract

United States
Xigen SA

Completed

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

Pain | Inflammation | Cataract

United States

Clinical Trials Sponsored by Urigen

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Kenya

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations